CD8A and cancer: In conclusion, our results support the notion that anti-tumour vaccination strategies should aim at the generation of both circulating and resident memory CD8+ T-cell subsets22, 23, 39, which could synergize with checkpoint antibody therapy for improved cancer immunotherapy.